SRX Global Takes Stake in Vistagen, Sees Undervalued Shares
VTGN sits 62% above its 52-week low of $0.198.
Summary
SRX Global, an AI-driven investment platform, has acquired a stake in Vistagen Therapeutics and views the shares as undervalued. The firm is open to engaging with Vistagen's leadership and board to discuss ways to unlock shareholder value. This follows a tumultuous period for Vistagen, including the June 30 failure of its lead drug candidate fasedienol in a Phase 3 trial and a going-concern warning in its June 15 annual report. The investment could signal confidence in the company's remaining pipeline or its intranasal platform, but no specific terms or size of the stake were disclosed. With a market cap around $10.9 million and shares trading at $0.32, any activist involvement could be material.
At the time of this announcement, VTGN was trading at $0.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.9M. The 52-week trading range was $0.20 to $5.14. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.